<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430909</article-id><article-id pub-id-type="pmcid-ver">PMC12430909.1</article-id><article-id pub-id-type="pmcaid">12430909</article-id><article-id pub-id-type="pmcaiid">12430909</article-id><article-id pub-id-type="pmid">40549441</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002744</article-id><article-id pub-id-type="publisher-id">IJS-D-24-06291</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Prospective Cohort Study</subject></subj-group></article-categories><title-group><article-title>Development and validation of a machine learning-based explainable predictive model for long-term net adverse clinical events in patients with high bleeding risk undergoing percutaneous coronary intervention: results from a prospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2448-9598</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="J">Junyan</given-names></name><degrees>MD</degrees><email>651874354@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lei</surname><given-names initials="Y">Yuting</given-names></name><degrees>MSc</degrees><email>1027518572@qq.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="R">Ran</given-names></name><degrees>PhD</degrees><email>283897787@qq.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="H">Hongsen</given-names></name><degrees>MSc</degrees><email>704804105@qq.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yuxiao</given-names></name><degrees>BSc</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="M">Minggang</given-names></name><degrees>MD</degrees><email>173072850@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Chen</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rao</surname><given-names initials="L">Li</given-names></name><degrees>MD</degrees><email>lrlz1989@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="D">Dapeng</given-names></name><degrees>MSc</degrees><email>867226280@qq.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="Z">Zhongxiu</given-names></name><degrees>MD</degrees><email>619087296@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="Y">Yong</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China</aff><aff id="aff2"><label>b</label>Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China</aff><aff id="aff3"><label>c</label>Information Center of West China Hospital, Sichuan University, Chengdu, China</aff><aff id="aff4"><label>d</label>West China School of Nursing, Sichuan University, Chengdu, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Department of Cardiology, West China Hospital of Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan 610041, China. Tel.: +86 18980608776; +86 18980602038. E-mail: <email>619087296@qq.com</email>(Z. Chen); E-mail: <email>heyongmd@wchscu.cn</email> (Y. He).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6082</fpage><lpage>6092</lpage><history><date date-type="received"><day>08</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>02</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyndlicense">https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">Creative Commons Attribution-NoDerivatives License 4.0</ext-link>, which allows for redistribution, commercial and noncommercial, as long as it is passed along unchanged and in whole, with credit to the author.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6082.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6082.pdf"/><abstract><sec><title>Background:</title><p>Patients classified as having a high bleeding risk (HBR) and undergoing percutaneous coronary intervention (PCI) face a significantly greater incidence of net adverse clinical events (NACEs) than non-HBR patients do. Existing risk assessment models, such as the CRUSADE and TIMI scores, do not adequately address the unique risks faced by the HBR population. There is an urgent need for a precise and comprehensive predictive model tailored to PCI-HBR patients to guide clinical decision-making and improve patient outcomes.</p></sec><sec><title>Methods:</title><p>This study aimed to develop a machine learning-based predictive model for long-term NACE in PCI-HBR patients. We utilized data from the Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients with Percutaneous Coronary Intervention and High Bleeding Risk registry database. Feature selection and interpretation were performed via a SHapley Additive exPlanations (SHAP) model based on recursive feature elimination. Model construction and evaluation were conducted via four algorithms: logistic regression, random forest, gradient boosting, and XGBoost.</p></sec><sec><title>Results:</title><p>A total of 1512 PCI-HBR patients were included in the study. The XGBoost model demonstrated the highest predictive performance, achieving an area under the receiver operating characteristic curve of 0.85. The SHAP model identified 24 significant variables contributing to the prediction of NACE, including clinical parameters, laboratory findings, and echocardiographic data.</p></sec><sec><title>Conclusions:</title><p>Our machine learning-based model offers a promising tool for predicting long-term NACE in PCI-HBR patients. The model&#8217;s high predictive accuracy and interpretability have the potential to enhance clinical decision-making and improve patient care. Further validation in larger, diverse populations is warranted to confirm these findings.</p></sec></abstract><kwd-group><kwd>high bleeding risk</kwd><kwd>machine learning</kwd><kwd>percutaneous coronary intervention</kwd><kwd>recursive feature elimination (RFE)</kwd><kwd>SHapley Additive exPlanations (SHAP)</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Percutaneous coronary intervention (PCI) is a widely utilized procedure for treating coronary artery disease<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>. However, high bleeding risk (HBR) patients, who represent approximately 40% of the PCI population, face significant challenges due to their increased susceptibility to bleeding complications and a higher propensity for ischemic events, resulting in poorer prognoses<sup>[<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]</sup>. For example, data from the Bern Registry indicate that the incidence of net adverse clinical events (NACE) is significantly higher in HBR patients than in non-HBR patients (19.3% vs. 8.8%)<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. Numerous studies have underscored the urgent need for precise risk assessment models tailored to this vulnerable cohort<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup>. While several prognostic models, such as the CRUSADE<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> and TIMI<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> scores, exist for PCI patients, they do not specifically address the unique risks faced by HBR patients. Current prediction models primarily focus on bleeding events, leaving a gap in comprehensive tools for guiding clinical decision-making in this population<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]</sup>.</p><p>Recently, machine learning has emerged as a powerful tool in cardiovascular disease, offering significant advantages in precision and individualized patient care<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>. These algorithms can analyze vast amounts of data to identify complex patterns that traditional methods might overlook, leading to more accurate predictions of patient outcomes and personalized treatment plans<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup>. In cardiovascular research, machine learning has successfully predicted various outcomes, from adverse events to optimal therapeutic strategies<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref>]</sup>. Given the pressing need for a dedicated prognostic model for PCI-HBR patients and the efficacy of machine learning in this field, this study aims to develop a predictive model to accurately forecast long-term NACE events in PCI-HBR patients post-discharge, ultimately enhancing clinical decision-making and improving patient outcomes.</p></sec><sec sec-type="methods"><title>Methods</title><p>We followed the Strengthening the Reporting of Cohort Studies in Surgery statement for reporting the study<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup>. The study was approved by the Biomedical Research Ethics Committee of the Biomedical Research Ethics Committee of West China Hospital (No. 2022&#8211;269), and all patients provided informed consent for the procedure as well as subsequent data collection and analysis for research. This study utilized data from the Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients with Percutaneous Coronary Intervention and High Bleeding Risk (PPP-PCI) registry database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05369442">NCT05369442</ext-link>), for which the protocol has been previously published<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>.</p></sec><sec><title>Study population</title><p>The study population consisted of all patients with PCI-HBR at West China Hospital, Sichuan University, from May 2022 to April 2024. The inclusion criteria were based on the Academic Research Consortium for high bleeding risk criteria<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup>. The study included patients who met either one primary criterion or two secondary criteria. Patients who refused follow-up were excluded from the study.</p></sec><sec><title>Study endpoint</title><p>The endpoint of this study is the 1-year NACE, which is defined as a composite endpoint encompassing all-cause mortality, recurrent myocardial infarction, ischemic stroke, and BARC 3&#8211;5 major bleeding. Each specific endpoint follows the definitions established by the ARC<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. NACE was chosen as the primary endpoint for the predictive model in this study because it comprehensively accounts for both ischemic and bleeding events in PCI-HBR patients. The specific follow-up plan and detailed definitions of the study endpoints can be found in our previously published protocol for the PPP-PCI study<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>.</p></sec><sec><title>Data collection</title><p>The collected variables included patients&#8217; baseline demographic data, comorbidities, laboratory test results, echocardiography data, coronary intervention parameters, and medication usage. The baseline demographic data, laboratory test results, and echocardiography data were based on the patient&#8217;s hospitalization for the current PCI procedure. Patients&#8217; baseline information was gathered from the Hospital Information System at West China Hospital, Sichuan University. Laboratory tests were conducted via the Laboratory Information System, and PCI-related procedural data were obtained from the internal database of the cardiac catheterization laboratory.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>First machine-learning model for long-term net adverse clinical events prediction in percutaneous coronary intervention-high bleeding risk patients, outperforming traditional models.</p></list-item><list-item><p>XGBoost model shows highest area under the receiver operating characteristic curve of 0.85, with SHapley Additive exPlanations (SHAP) identifying 24 significant variables for prediction.</p></list-item><list-item><p>A recursive feature elimination-SHAP analysis method is proposed, enhancing model transparency and interpretability.</p></list-item><list-item><p>Model integrated into web app for clinical use, but requires external validation.</p></list-item></list></p></sec></boxed-text></p></sec><sec><title>Data processing</title><p>In this study, all baseline indicators were obtained from the parameters recorded during the initial visit at the time of enrollment. If a parameter was not tested or examined during this visit, it was considered a missing value. In cases where a parameter underwent multiple tests or examinations during the initial visit, the result from the most recent test prior to the PCI procedure was selected. The K-nearest neighbors method was used to impute missing data, and datasets with more than 15% missing values were excluded from subsequent analyses. Simultaneously, we utilized a downsampling approach, whereby we selected a cohort of patients without NACE events that matched the number of patients with NACE events for subsequent analysis.</p></sec><sec><title>Machine learning algorithms</title><sec sec-type="discussion"><title>Feature selection and feature interpretation</title><p>In this study, we employ a SHapley Additive exPlanations (SHAP) model architecture<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>, integrated with Recursive Feature Elimination (RFE)<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup>, to perform feature selection and analysis. The RFE model identifies the most and least important features, iteratively removing them from the feature set until all features have been evaluated. This process yields a ranked list of features and identifies an optimal subset for modeling.</p><p>The SHAP model, grounded in cooperative game theory and the Shapley value, interprets model outputs by calculating the marginal contribution of each feature to the predictions. Specifically, SHAP assesses the average contribution of each feature across all possible combinations, thereby determining its impact on the final predictions. In our research, we first utilize the RFE model to identify the optimal subset of features, followed by SHAP analysis to provide consistent and precise attribution values for each feature, elucidating the relationship between input features and NACE classifications.</p></sec></sec><sec><title>Model construction and evaluation</title><p>We randomly divided the dataset into training and validation sets at a ratio of 8:2 (training set: validation set). For each of the machine learning algorithms, the training set was employed to train the models, and the validation set was utilized to assess their performance. On the basis of the results of the training and validation, we select the model with the best performance for subsequent feature analysis. During the feature selection process via RFE, model prediction is performed simultaneously, with the stability of the model prediction being contingent upon the stability of the underlying algorithm. If the underlying algorithm is stable, then RFE will also exhibit stability; conversely, if the underlying algorithm is unstable, RFE will likewise be unstable. Given the unknown distribution of the data, we select four underlying algorithms from both linear and nonlinear perspectives. Logistic regression is classified as a linear algorithm, whereas random forest, gradient boosting decision trees (GBDTs), and XGBoost are categorized as nonlinear ensemble algorithms that have been widely applied in the fields of computer science and medicine. Specifically, we conducted RFE modeling for each of the four algorithms, utilizing a dataset comprising 75 features. Consequently, each algorithm iteratively constructs 75 models, uses the area under the receiver operating characteristic curve (AUC) as the evaluation metric for model prediction, and ultimately determines the optimal algorithm and the optimal subset of features.</p><p>This study employed a procedural programming approach using the open-source machine learning library scikit-learn in Python 3.6, with a computer equipped with an Intel Core i7-10870H CPU operating at 2.2&#160;GHz and 32 GB of RAM.</p></sec><sec><title>Statistical analysis</title><p>Descriptive statistics were utilized to provide an overview of the basic characteristics and comorbidities of the study population. Continuous variables are described as the mean&#160;&#177; standard deviation (SD) if they followed a normal distribution; otherwise, they are presented as the median and interquartile range (IQR). Categorical variables are reported as counts and percentages.</p><p>For categorical variables, either the chi-square test or Fisher&#8217;s exact test was employed, as appropriate. For continuous variables, normality was assessed via Shapiro&#8210;Wilk tests and visual inspection of Q&#8210;Q plots. If both groups met the normality assumption, parametric analysis (independent samples <italic toggle="yes">t</italic>-test) was performed, with the results reported as the means&#160;&#177; SDs. For nonnormally distributed data, nonparametric analysis (Mann&#8210;Whitney <italic toggle="yes">U</italic> test) was used, with outcomes expressed as medians and IQRs. Data analysis was performed via R version 4.1.2. Statistical significance was defined as a two-sided <italic toggle="yes">P</italic> value &lt;0.05.</p></sec><sec sec-type="results"><title>Results</title></sec><sec><title>Baseline characteristics</title><p>According to the inclusion and exclusion criteria, 1512 patients with a PCI-HBR were eligible for this study. Figure <xref rid="F1" ref-type="fig">1</xref> presents a comprehensive flowchart outlining the detailed research process.
<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Flowchart of the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g001.jpg"/></fig>
</p><p>The baseline information, comorbidities, and laboratory findings of the included patients are summarized in Table <xref rid="T1" ref-type="table">1</xref>.
<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Group 1 (NACE&#160;=&#160;0, <italic toggle="yes">n</italic> =&#160;1360)</th><th align="left" rowspan="1" colspan="1">Group 2 (NACE&#160;=&#160;1, <italic toggle="yes">n</italic> =&#160;152)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male (%)</td><td align="center" rowspan="1" colspan="1">977 (71.8%)</td><td align="center" rowspan="1" colspan="1">105 (69.5%)</td><td align="center" rowspan="1" colspan="1">0.627<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking (%)</td><td align="center" rowspan="1" colspan="1">223 (16.4%)</td><td align="center" rowspan="1" colspan="1">37 (24.5%)</td><td align="center" rowspan="1" colspan="1">0.017<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Drinking (%)</td><td align="center" rowspan="1" colspan="1">117 (8.6%)</td><td align="center" rowspan="1" colspan="1">5 (3.3%)</td><td align="center" rowspan="1" colspan="1">0.035<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beats/min)</td><td align="center" rowspan="1" colspan="1">77.0 (68.0&#8211;87.0)</td><td align="center" rowspan="1" colspan="1">78.0 (71.0&#8211;87.0)</td><td align="center" rowspan="1" colspan="1">0.358<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">131.0 (118.0&#8211;146.0)</td><td align="center" rowspan="1" colspan="1">132.0 (115.0&#8211;149.0)</td><td align="center" rowspan="1" colspan="1">0.403<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">77.0 (70.0&#8211;85.0)</td><td align="center" rowspan="1" colspan="1">77.0 (70.0&#8211;86.0)</td><td align="center" rowspan="1" colspan="1">0.381<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">64.0 (55.0&#8211;70.9)</td><td align="center" rowspan="1" colspan="1">61.0 (55.0&#8211;68.0)</td><td align="center" rowspan="1" colspan="1">0.036<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">163.0 (157.0&#8211;169.0)</td><td align="center" rowspan="1" colspan="1">160.0 (155.0&#8211;168.0)</td><td align="center" rowspan="1" colspan="1">0.002<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Acute coronary syndrome (%)</td><td align="center" rowspan="1" colspan="1">699 (51.4%)</td><td align="center" rowspan="1" colspan="1">73 (48.3%)</td><td align="center" rowspan="1" colspan="1">0.537<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" rowspan="1" colspan="1">808 (59.4%)</td><td align="center" rowspan="1" colspan="1">100 (66.2%)</td><td align="center" rowspan="1" colspan="1">0.122<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (%)</td><td align="center" rowspan="1" colspan="1">545 (40.0%)</td><td align="center" rowspan="1" colspan="1">75 (49.7%)</td><td align="center" rowspan="1" colspan="1">0.028<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia (%)</td><td align="center" rowspan="1" colspan="1">400 (29.4%)</td><td align="center" rowspan="1" colspan="1">47 (31.1%)</td><td align="center" rowspan="1" colspan="1">0.727<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation (%)</td><td align="center" rowspan="1" colspan="1">106 (7.8%)</td><td align="center" rowspan="1" colspan="1">18 (11.9%)</td><td align="center" rowspan="1" colspan="1">0.110<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke (%)</td><td align="center" rowspan="1" colspan="1">86 (6.3%)</td><td align="center" rowspan="1" colspan="1">11 (7.3%)</td><td align="center" rowspan="1" colspan="1">0.776<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke (%)</td><td align="center" rowspan="1" colspan="1">6 (0.4%)</td><td align="center" rowspan="1" colspan="1">2 (1.3%)</td><td align="center" rowspan="1" colspan="1">0.407<xref rid="tbl1-fn3" ref-type="table-fn">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic kidney disease (%)</td><td align="center" rowspan="1" colspan="1">279 (20.5%)</td><td align="center" rowspan="1" colspan="1">63 (41.7%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Gout (%)</td><td align="center" rowspan="1" colspan="1">115 (8.4%)</td><td align="center" rowspan="1" colspan="1">14 (9.3%)</td><td align="center" rowspan="1" colspan="1">0.850<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease (%)</td><td align="center" rowspan="1" colspan="1">76 (5.6%)</td><td align="center" rowspan="1" colspan="1">10 (6.6%)</td><td align="center" rowspan="1" colspan="1">0.736<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Peptic ulcer (%)</td><td align="center" rowspan="1" colspan="1">37 (2.7%)</td><td align="center" rowspan="1" colspan="1">6 (4.0%)</td><td align="center" rowspan="1" colspan="1">0.534<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary infection (%)</td><td align="center" rowspan="1" colspan="1">142 (10.4%)</td><td align="center" rowspan="1" colspan="1">12 (7.9%)</td><td align="center" rowspan="1" colspan="1">0.414<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">IVUS-guided PCI (%)</td><td align="center" rowspan="1" colspan="1">256 (18.8%)</td><td align="center" rowspan="1" colspan="1">29 (19.2%)</td><td align="center" rowspan="1" colspan="1">0.993<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">OCT-guided PCI (%)</td><td align="center" rowspan="1" colspan="1">52 (3.8%)</td><td align="center" rowspan="1" colspan="1">5 (3.3%)</td><td align="center" rowspan="1" colspan="1">0.931<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">FFR-guided PCI (%)</td><td align="center" rowspan="1" colspan="1">62 (4.6%)</td><td align="center" rowspan="1" colspan="1">5 (3.3%)</td><td align="center" rowspan="1" colspan="1">0.620<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Transfer to CCU (%)</td><td align="center" rowspan="1" colspan="1">183 (13.4%)</td><td align="center" rowspan="1" colspan="1">17 (11.3%)</td><td align="center" rowspan="1" colspan="1">0.531<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Left main stem lesion (%)</td><td align="center" rowspan="1" colspan="1">261 (19.2%)</td><td align="center" rowspan="1" colspan="1">48 (31.8%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Multivessel disease (%)</td><td align="center" rowspan="1" colspan="1">561 (41.2%)</td><td align="center" rowspan="1" colspan="1">101 (66.9%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Femoral access (%)</td><td align="center" rowspan="1" colspan="1">17 (1.2%)</td><td align="center" rowspan="1" colspan="1">1 (0.7%)</td><td align="center" rowspan="1" colspan="1">0.814<xref rid="tbl1-fn3" ref-type="table-fn">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Intra-aortic balloon pump (%)</td><td align="center" rowspan="1" colspan="1">42 (3.1%)</td><td align="center" rowspan="1" colspan="1">9 (6.0%)</td><td align="center" rowspan="1" colspan="1">0.106<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic total occlusion (%)</td><td align="center" rowspan="1" colspan="1">312 (22.9%)</td><td align="center" rowspan="1" colspan="1">38 (25.2%)</td><td align="center" rowspan="1" colspan="1">0.605<xref rid="tbl1-fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LV (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">49.0 (46.0&#8211;54.0)</td><td align="center" rowspan="1" colspan="1">48.0 (45.0&#8211;54.0)</td><td align="center" rowspan="1" colspan="1">0.210<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LA (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">37.0 (34.0&#8211;40.0)</td><td align="center" rowspan="1" colspan="1">37.0 (35.0&#8211;41.0)</td><td align="center" rowspan="1" colspan="1">0.142<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">RV (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">22.0 (20.0&#8211;23.0)</td><td align="center" rowspan="1" colspan="1">21.0 (20.0&#8211;23.0)</td><td align="center" rowspan="1" colspan="1">0.273<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">RA (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">34.0 (32.0&#8211;38.0)</td><td align="center" rowspan="1" colspan="1">33.0 (31.0&#8211;37.2)</td><td align="center" rowspan="1" colspan="1">0.045<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">IVS (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">12.0 (10.0&#8211;13.5)</td><td align="center" rowspan="1" colspan="1">11.0 (10.0&#8211;13.9)</td><td align="center" rowspan="1" colspan="1">0.286<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LVPW (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">9.1 (9.0&#8211;10.0)</td><td align="center" rowspan="1" colspan="1">9.0 (9.0&#8211;10.0)</td><td align="center" rowspan="1" colspan="1">0.021<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">AAO (mm)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">35.7 (34.0&#8211;39.0)</td><td align="center" rowspan="1" colspan="1">35.0 (33.5&#8211;38.5)</td><td align="center" rowspan="1" colspan="1">0.216<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">EF(%)<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">61.0 (50.0&#8211;68.0)</td><td align="center" rowspan="1" colspan="1">60.0 (51.0&#8211;68.0)</td><td align="center" rowspan="1" colspan="1">0.360<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hb (g/L)</td><td align="center" rowspan="1" colspan="1">124.1 (110.0&#8211;140.0)</td><td align="center" rowspan="1" colspan="1">114.0 (101.0&#8211;131.5)</td><td align="left" rowspan="1" colspan="1">&lt;0.001<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">PLT (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">179.0 (136.0&#8211;225.0)</td><td align="center" rowspan="1" colspan="1">190.0 (140.0&#8211;220.0)</td><td align="center" rowspan="1" colspan="1">0.371<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">6.7 (5.4&#8211;8.5)</td><td align="center" rowspan="1" colspan="1">6.7 (5.4&#8211;8.1)</td><td align="center" rowspan="1" colspan="1">0.306<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Neu (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">4.4 (3.4&#8211;6.0)</td><td align="center" rowspan="1" colspan="1">4.3 (3.3&#8211;5.9)</td><td align="center" rowspan="1" colspan="1">0.266<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">RBC (&#215;10<sup>12</sup>/L)</td><td align="center" rowspan="1" colspan="1">4.2 (3.7&#8211;4.6)</td><td align="center" rowspan="1" colspan="1">4.1 (3.6&#8211;4.5)</td><td align="center" rowspan="1" colspan="1">0.098<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">HBDH (U/L)</td><td align="center" rowspan="1" colspan="1">157.0 (133.0&#8211;206.0)</td><td align="center" rowspan="1" colspan="1">150.0 (134.5&#8211;210.0)</td><td align="center" rowspan="1" colspan="1">0.390<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.5 (1.1&#8211;2.1)</td><td align="center" rowspan="1" colspan="1">1.5 (1.1&#8211;2.4)</td><td align="center" rowspan="1" colspan="1">0.201<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Glu (mmol/L)</td><td align="center" rowspan="1" colspan="1">7.0 (5.6&#8211;10.0)</td><td align="center" rowspan="1" colspan="1">7.3 (5.9&#8211;10.1)</td><td align="center" rowspan="1" colspan="1">0.050<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#946;-HB (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.1 (0.1&#8211;0.2)</td><td align="center" rowspan="1" colspan="1">0.1 (0.1&#8211;0.2)</td><td align="center" rowspan="1" colspan="1">0.006<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">AG (mmol/L)</td><td align="center" rowspan="1" colspan="1">15.2 (10.8&#8211;17.6)</td><td align="center" rowspan="1" colspan="1">16.1 (13.6&#8211;18.1)</td><td align="left" rowspan="1" colspan="1">&lt;0.001<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">CO2 (mmol/L)</td><td align="center" rowspan="1" colspan="1">22.8 (20.6&#8211;24.7)</td><td align="center" rowspan="1" colspan="1">22.4 (20.6&#8211;24.0)</td><td align="center" rowspan="1" colspan="1">0.050<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">MCV (fL)</td><td align="center" rowspan="1" colspan="1">93.5 (90.3&#8211;96.9)</td><td align="center" rowspan="1" colspan="1">93.3 (90.0&#8211;96.5)</td><td align="center" rowspan="1" colspan="1">0.290<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Monocyte (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">0.5 (0.4&#8211;0.7)</td><td align="center" rowspan="1" colspan="1">0.5 (0.4&#8211;0.7)</td><td align="center" rowspan="1" colspan="1">0.500<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocyte (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">1.4 (1.0&#8211;1.8)</td><td align="center" rowspan="1" colspan="1">1.3 (1.0&#8211;1.8)</td><td align="center" rowspan="1" colspan="1">0.455<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">CTnT (ng/mL)</td><td align="center" rowspan="1" colspan="1">23.1 (11.3&#8211;295.9)</td><td align="center" rowspan="1" colspan="1">39.1 (16.1&#8211;407.8)</td><td align="left" rowspan="1" colspan="1">&lt;0.001<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Myo (ng/mL)</td><td align="center" rowspan="1" colspan="1">41.0 (28.0&#8211;86.0)</td><td align="center" rowspan="1" colspan="1">43.4 (29.9&#8211;85.7)</td><td align="center" rowspan="1" colspan="1">0.214<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">CK-MB (U/L)</td><td align="center" rowspan="1" colspan="1">2.0 (1.3&#8211;3.8)</td><td align="center" rowspan="1" colspan="1">2.0 (1.4&#8211;3.8)</td><td align="center" rowspan="1" colspan="1">0.323<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NT-ProBNP (pg/mL)</td><td align="center" rowspan="1" colspan="1">589.0 (152.0&#8211;2268.0)</td><td align="center" rowspan="1" colspan="1">860.0 (146.5&#8211;2488.5)</td><td align="center" rowspan="1" colspan="1">0.085<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="center" rowspan="1" colspan="1">23.0 (18.0&#8211;42.0)</td><td align="center" rowspan="1" colspan="1">21.0 (17.0&#8211;35.0)</td><td align="center" rowspan="1" colspan="1">0.059<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">22.0 (14.0&#8211;43.0)</td><td align="center" rowspan="1" colspan="1">18.0 (13.0&#8211;32.0)</td><td align="center" rowspan="1" colspan="1">0.004<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LDH (U/L)</td><td align="center" rowspan="1" colspan="1">211.0 (175.0&#8211;336.0)</td><td align="center" rowspan="1" colspan="1">199.0 (167.5&#8211;285.5)</td><td align="center" rowspan="1" colspan="1">0.042<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">ALB (g/L)</td><td align="center" rowspan="1" colspan="1">41.2 (36.6&#8211;44.3)</td><td align="center" rowspan="1" colspan="1">40.4 (37.4&#8211;43.8)</td><td align="center" rowspan="1" colspan="1">0.296<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LDLC (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.8 (1.2&#8211;2.4)</td><td align="center" rowspan="1" colspan="1">1.7 (1.2&#8211;2.4)</td><td align="center" rowspan="1" colspan="1">0.425<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">UA (&#956;mol/L)</td><td align="center" rowspan="1" colspan="1">341.0 (265.0&#8211;428.0)</td><td align="center" rowspan="1" colspan="1">329.0 (270.0&#8211;431.0)</td><td align="center" rowspan="1" colspan="1">0.477<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min/1.73&#160;m2)</td><td align="center" rowspan="1" colspan="1">64.9 (42.5&#8211;85.4)</td><td align="center" rowspan="1" colspan="1">61.6 (39.2&#8211;83.3)</td><td align="center" rowspan="1" colspan="1">0.090<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Na (mmol/L)</td><td align="center" rowspan="1" colspan="1">138.7 (136.3&#8211;140.7)</td><td align="center" rowspan="1" colspan="1">138.5 (136.5&#8211;140.7)</td><td align="center" rowspan="1" colspan="1">0.472<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">K (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.0 (3.6&#8211;4.3)</td><td align="center" rowspan="1" colspan="1">4.1 (3.8&#8211;4.4)</td><td align="center" rowspan="1" colspan="1">0.024<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Ca (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1&#8211;2.3)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1&#8211;2.3)</td><td align="center" rowspan="1" colspan="1">0.374<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Cys-c<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (mg/L)</td><td align="center" rowspan="1" colspan="1">1.1 (0.8&#8211;1.4)</td><td align="center" rowspan="1" colspan="1">1.2 (0.9&#8211;1.6)</td><td align="center" rowspan="1" colspan="1">0.007<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Total protein (g/L)</td><td align="center" rowspan="1" colspan="1">66.5 (60.8&#8211;70.4)</td><td align="center" rowspan="1" colspan="1">66.8 (61.8&#8211;71.8)</td><td align="center" rowspan="1" colspan="1">0.092<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">9.6 (6.9&#8211;12.4)</td><td align="center" rowspan="1" colspan="1">9.4 (7.1&#8211;12.1)</td><td align="center" rowspan="1" colspan="1">0.489<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">HBA1C<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (%)</td><td align="center" rowspan="1" colspan="1">6.6 (5.9&#8211;8.3)</td><td align="center" rowspan="1" colspan="1">6.5 (5.9&#8211;8.4)</td><td align="center" rowspan="1" colspan="1">0.312<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">PCT<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td><td align="center" rowspan="1" colspan="1">0.087<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">D-Dimer<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (mg/L FEU)</td><td align="center" rowspan="1" colspan="1">0.5 (0.3&#8211;1.0)</td><td align="center" rowspan="1" colspan="1">0.5 (0.3&#8211;1.3)</td><td align="center" rowspan="1" colspan="1">0.030<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">INR<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">1.0 (0.9&#8211;1.1)</td><td align="center" rowspan="1" colspan="1">1.0 (0.9&#8211;1.1)</td><td align="center" rowspan="1" colspan="1">0.482<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">APTT<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (s)</td><td align="center" rowspan="1" colspan="1">28.2 (26.3&#8211;30.4)</td><td align="center" rowspan="1" colspan="1">27.7 (25.8&#8211;30.1)</td><td align="center" rowspan="1" colspan="1">0.036<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Fib<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (g/L)</td><td align="center" rowspan="1" colspan="1">2.8 (2.2&#8211;3.6)</td><td align="center" rowspan="1" colspan="1">3.0 (2.3&#8211;3.7)</td><td align="center" rowspan="1" colspan="1">0.200<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">FDP<xref rid="tbl1-fn1" ref-type="table-fn">a</xref> (mg/L)</td><td align="center" rowspan="1" colspan="1">2.5 (2.5&#8211;2.5)</td><td align="center" rowspan="1" colspan="1">2.5 (2.5&#8211;3.2)</td><td align="center" rowspan="1" colspan="1">0.076<xref rid="tbl1-fn4" ref-type="table-fn">d</xref></td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CAD, coronary artery disease; IVUS, intravascular ultrasound; PCI, percutaneous coronary intervention; OCT, optical coherence tomography; FFR, fractional flow reserve; CCU, coronary care unit; LV, left ventricle; LA, left atrium; RV, right ventricle; RA, right atrium; IVS, interventricular septum; LVPW, left ventricular posterior wall; AAO, ascending aorta; EF, ejection fraction; Hb, hemoglobin; PLT, platelet; WBC, white blood cell; Neu, neutrophil; RBC, red blood cell; HBDH, hydroxybutyrate dehydrogenase; TG, triglyceride; Glu, glucose; &#946;-HB, beta-hydroxybutyrate; AG, anion gap; CO<sub>2</sub>, carbon dioxide; MCV, mean corpuscular volume; Lymph, lymphocyte; CTnT, cardiac troponin T; Myo, myoglobin; CK-MB, creatine kinase-MB; NT-ProBNP, N-terminal pro b-type natriuretic peptide; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALB, albumin; LDLC, low-density lipoprotein cholesterol; UA, uric acid; eGFR, estimated glomerular filtration rate; Na, sodium; K, potassium; Ca, calcium; Cys-c, serum cystatin C; HBA</p></fn><fn id="tbl1-fn1"><label><sup>a</sup></label><p>The variables marked indicate those that have been imputed, with 100 imputations for LV, LA, RV, RA, IVS, LVPW, AAO, and EF; 202 imputations for Cys-c; 198 imputations for HBA1C; 229 for PCT; and 97 imputations for INR, APTT, Fib, and FDP.</p></fn><fn id="tbl1-fn2"><label><sup>b</sup></label><p>Chi-square test.</p></fn><fn id="tbl1-fn3"><label><sup>c</sup></label><p>Fisher&#8217;s exact test.</p></fn><fn id="tbl1-fn4"><label><sup>d</sup></label><p>Mann&#8210;Whitney <italic toggle="yes">U</italic> test.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Model development and validation</title><p>We randomly divided the entire dataset into training and validation sets using an 8:2 split ratio. The patient data associated with NACE events were employed to construct four distinct predictive models: logistic regression, random forest, XGBoost, and gradient boosting. These models were subsequently evaluated on the validation set.</p><p>As shown in Figure <xref rid="F2" ref-type="fig">2</xref>, comparative analysis revealed that XGBoost outperformed the other models, attaining the highest AUC value of 0.85. Random forest and gradient boosting demonstrated moderate performance, with AUC values of 0.82 and 0.79, respectively. In contrast, conventional logistic regression showed the weakest predictive capability, yielding an AUC of only 0.73.
<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>ROC curves of the four models.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g002.jpg"/></fig>
</p><p>The performance of the four models across varying numbers of features is illustrated in Figure <xref rid="F3" ref-type="fig">3</xref>. The results indicate that the traditional logistic regression model exhibits an initial increase in performance, which is subsequently followed by a decline as the number of features increases. In contrast, the predictive performance of the other three machine learning models tends to stabilize with the gradual increase in feature count.
<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>AUCs of the four models with various numbers of features.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g003.jpg"/></fig>
</p><p>Table <xref rid="T2" ref-type="table">2</xref> presents the number of features corresponding to the optimal predictive performance of the four different models, along with their best predictive capabilities, including parameters such as the AUC, sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and F1 score. Thus, we select the XGBoost model as the best-performing model, and we explain the model in the following sections.
<table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>The number of features that achieve the best predictive performance among the four models, along with the optimal performance of each model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Model</th><th align="left" rowspan="1" colspan="1">Features</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Sensitivity</th><th align="left" rowspan="1" colspan="1">Specificity</th><th align="left" rowspan="1" colspan="1">PPV</th><th align="left" rowspan="1" colspan="1">NPV</th><th align="left" rowspan="1" colspan="1">Accuracy</th><th align="left" rowspan="1" colspan="1">F1 score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">XGBoost</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">0.85</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Random Forest</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1">0.69</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Gradient Boosting</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1">0.75</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic Regression</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">0.66</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.69</td><td align="center" rowspan="1" colspan="1">0.69</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Model explanation</title><p>In the clinical application of predictive models, the transparency and interpretability of the model are crucial. SHAP is an explanation method based on cooperative game theory that quantifies the contribution of each feature to the prediction outcome by calculating the Shapley values of the features. The fundamental idea is to consider all possible combinations of features and assess the marginal contribution of each feature within different combinations, thereby deriving the average contribution of each feature to the model&#8217;s prediction results.</p><p>The transparency of SHAP allows us to clearly observe the positive and negative impacts of each feature on the prediction outcome, enabling a deeper understanding of the model&#8217;s decision-making mechanism. Additionally, it provides global explanations for the entire model as well as local explanations for each individual prediction instance. Figure <xref rid="F4" ref-type="fig">4</xref> provides a summary of the SHAP value plot, which integrates feature importance with feature effects within the optimal model, XGBoost. A total of 24 variables were identified as significant. Notably, coronary parameters (multivessel disease), echocardiographic parameters (left atrial [LA], left ventricular ejection fraction [LVEF]), and biochemical markers (blood glucose, &#946;-hydroxybutyrate [&#946;-HB]), total triglycerides, total cholesterol, etc.) have emerged as relatively important features for predicting NACE. Additionally, parameters from routine blood tests (hemoglobin, absolute lymphocyte count, white blood cell count, platelet count, etc.), coagulation tests activated partial thromboplastin time (APTTs), and myocardial enzymes (cTnT, CK-MB) were also recognized as important predictors.
<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>SHAP summary dot plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g004.jpg"/></fig>
</p><p>Figure <xref rid="F5" ref-type="fig">5</xref> illustrates the relationships between the actual values and the SHAP values of the nine key features. SHAP values greater than zero indicate a positive class prediction within the model, signifying an increased risk of NACE. For example, patients with hemoglobin levels below 110&#160;g/L or an international normalized ratio (INR) below 1.0 demonstrated SHAP values exceeding zero, thereby increasing the likelihood of experiencing a NACE event. Furthermore, an actual LA value of &#8805;40 mm and a glucose level of &#8805;10&#160;mmol/L also contributed to the model&#8217;s classification toward the &#8220;NACE&#8221; category. Additional information regarding the remaining features can be found in Figure <xref rid="F5" ref-type="fig">5</xref>.
<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>SHAP dependence plot. Each dependence plot shows how a single feature affects the output of the prediction model, and nine core features are presented in the figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g005.jpg"/></fig>
</p><p>We also transformed the output results into a quantitative score via propensity scores, which we designated the NACE score. We output all samples from the test set in terms of their propensity scores and plotted the kernel density estimate of the probability distribution, as shown in Figure <xref rid="F6" ref-type="fig">6</xref>. In the figure, the <italic toggle="yes">x</italic>-axis represents the score, whereas the <italic toggle="yes">y</italic>-axis represents the probability distribution. The model exhibits a lower distribution in the 50-point range than in the 20-point and 75-point ranges, indicating that the model possesses a more decisive decision-making capability. The observed bimodal distribution pattern (Kolmogorov&#8210;Smirnov test, <italic toggle="yes">P</italic> &lt; 0.001) also validated the strong discriminatory ability of the scores.
<fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p>KDE plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g006.jpg"/></fig>
</p></sec><sec><title>Convenient application for clinical utility</title><p>The final prediction model has been integrated into a web application to enhance its practical use in clinical settings, as illustrated in Figure <xref rid="F7" ref-type="fig">7</xref>. By inputting the actual values of the eight features necessary for the model, the application automatically estimates the risk of AKI for a specific child. The web application can be accessed online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://182.254.134.142/prediction/" ext-link-type="uri">http://182.254.134.142/prediction/</ext-link>.
<fig position="float" id="F7" orientation="portrait"><label>Figure 7.</label><caption><p>A simple application for predicting long-term NACE events in PCI-HBR patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6082-g007.jpg"/></fig>
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The PCI-HBR population is at an extremely high risk due to elevated bleeding and ischemic risks<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R20" ref-type="bibr">20</xref>]</sup>. Previous studies have shown a significantly higher incidence of adverse events in this group compared to non-HBR patients<sup>[<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>]</sup>. Thus, developing a precise assessment system is crucial for improving their prognosis.</p><p>This study is the first to use machine-learning models to predict long-term NACE in PCI-HBR patients. Our results show that machine-learning models outperform traditional ones, such as logistic regression, in predicting long-term adverse events.</p><p>Existing prediction models for PCI-HBR patients mainly focus on major bleeding risk rather than survival outcomes<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup>. Scoring systems like CRUSADE<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> and TIMI<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> are not tailored to the HBR population, making them less accurate in predicting the overall prognosis of PCI-HBR patients. Our machine-learning-based prognostic model with NACE as the endpoint incorporates nearly all available variables, offering a more comprehensive approach.</p><p>Machine learning has advantages over traditional methods. It can automatically identify patterns in large, complex, and high-dimensional datasets, enabling personalized treatment recommendations and capturing nonlinear relationships in medical data while minimizing human bias<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup>. In this study, we employed three tree-based machine learning models, random forest, XGBoost, and GBDTs, with AUC values of 0.82, 0.85, and 0.78, respectively, all outperforming the traditional logistic regression model (AUC&#160;=&#160;0.76). The superior predictive performance of the ML models can be attributed to several key mechanisms. First, ML models can handle high-dimensional and complex nonlinear relationships, making them particularly advantageous when dealing with medical data that include numerous variables and intricate interactions. Second, tree-based models, by integrating multiple decision trees, can capture significant features and patterns within the data, thus enhancing the accuracy and robustness of predictions. Additionally, ML models can be further optimized through techniques such as cross-validation and hyperparameter tuning, which help minimize the risk of overfitting and provide more reliable predictive outcomes.</p><p>We used an RFE-SHAP analysis method. SHAP quantifies feature contributions via Shapley values, enhancing model transparency and interpretability<sup>[<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>]</sup>. RFE selects important features. This integrated approach ensures high performance while providing clear explanations.</p><p>We ranked the importance of variables within the predictive models and found that hemoglobin level was the most significant variable. Numasawa <italic toggle="yes">et al</italic><sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> conducted a multicenter registry study that demonstrated that low hemoglobin levels are significantly associated with a higher risk of bleeding and adverse outcomes in PCI patients. Low hemoglobin can lead to tissue hypoxia, increasing the risk of cardiovascular events and thereby affecting long-term survival<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. Additionally, in our study, multivessel disease was identified as another key risk factor, which increases the complexity of the procedure and the risk of postoperative complications. Bahit <italic toggle="yes">et al</italic><sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> demonstrated through a systematic review that multivessel disease is associated with high rates of major adverse cardiovascular events early after myocardial infarction that persist at 1 year. Interestingly, in addition to the well-known and widely recognized risk factors included in the final model, this study identified several characteristics that may not be of significant concern to cardiovascular clinicians and might even be overlooked. For example, we found that an increase in LA diameter is a strong predictor of 2-year NACE events, although a prior report by Kizer <italic toggle="yes">et al</italic><sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> indicated that LA diameter independently predicts incident cardiovascular events in middle-aged and elderly adults.</p><p>Our study also revealed that higher levels of &#946;-HB and anion gap (AG) are associated with an increased likelihood of experiencing NACE in PCI-HBR patients. This finding is consistent with previous research, suggesting that elevated &#946;-HB and AG may indicate severe metabolic disturbances, such as ketoacidosis or lactic acidosis, which may exacerbate myocardial injury, impair cardiac function, and increase the risk of arrhythmias, ultimately leading to poorer prognoses for PCI-HBR patients<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup>. For example, Dai <italic toggle="yes">et al</italic><sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> reported that among patients with ST-elevation myocardial infarction undergoing PCI, those in the highest &#946;-HB group (&gt;0.28&#160;mmol/L) presented a significantly greater incidence of in-hospital major adverse cardiovascular events (20.9%) than did those in the low (10.5%) and moderate (14.9%) &#946;-HB groups. Furthermore, multiple studies have demonstrated that a higher AG (including albumin-corrected AG) at the time of admission in acute myocardial infarction patients is positively correlated with all-cause mortality at 30&#160;days, 180&#160;days, and 1 year, a relationship that remains consistent across various subgroup analyses<sup>[<xref rid="R32" ref-type="bibr">32</xref>&#8211;<xref rid="R34" ref-type="bibr">34</xref>]</sup>. Furthermore, other indicators, such as the INR and absolute lymphocyte count, were also identified as having adverse prognostic implications for PCI-HBR patients. The prognostic value of these features warrants further validation specifically within this special population.</p><p>In the future, we aim to optimize the predictive models by integrating more clinical variables and biomarkers. We also plan to validate these models in larger, multicenter studies to ensure their effectiveness and generalizability across diverse patient populations. This will help in early identification of high-risk patients and formulation of individualized treatment plans, ultimately improving the long-term prognosis of PCI-HBR patients.</p></sec><sec><title>Limitations</title><p>This study has several limitations that warrant consideration. First, the data utilized in this research were derived from a single national registry cohort in China (PPP-PCI). Previous studies have indicated that bleeding risk may vary significantly among patients from different geographical regions. Therefore, future research should incorporate data from other countries to validate the model developed in this study. Second, both model development and validation were performed using a single dataset, which precludes the inclusion of external validation data from other centers. Cultural, procedural, and healthcare system differences among countries might affect the model&#8217;s international generalizability. Future research should include data from multiple centers and locations to improve this and do the external validation. Finally, machine learning models typically require a large amount of data to effectively learn the patterns and relationships within the dataset. An insufficient sample size may hinder the model&#8217;s ability to adequately capture the complexity of the data during the training process. In this study, considering the impact of positive and negative balance, the total sample size was just over 300 cases, which may affect the model&#8217;s performance and reliability.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, this study first presents a robust machine learning model that effectively predicts long-term NACEs in PCI-HBR patients, outperforming traditional models with enhanced interpretability through SHAP values. This advancement signifies a step forward in personalized cardiovascular care, offering clinicians a valuable tool for improved risk assessment and decision-making. However, it is important to note that while the current model performance is promising, it requires external validation before routine clinical implementation.</p></sec></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><fn-group><fn fn-type="other"><p>J.Z. and Y.L. contributed equally to this work.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 23 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>The study was approved by the Biomedical Research Ethics Committee of West China Hospital, Sichuan University. All patients provided informed consent for the procedure as well as for subsequent data collection and analysis for research purposes.</p></sec><sec><title>Consent</title><p>The study was approved by the Biomedical Research Ethics Committee of West China Hospital (No.2022-269) and all patients provided informed consent for the procedure as well as the subsequent data collection and analysis for research.</p></sec><sec><title>Sources of funding</title><p>This study was funded by grants from the Natural Science Foundation of China (grant number 82100282), the Sichuan Provincial Department of Science and Technology Natural Science Foundation Youth Fund Project (grant number 24NSFSC2970), the 1.3.5 project for disciplines of excellence&#8211;Clinical Research Incubation Project, West China Hospital, Sichuan University (grant number: 2021HXFH021), and the Key Research and Development Programs of Sichuan Province (grant numbers: 21ZDYF1287).</p></sec><sec><title>Author contributions</title><p>J.Z. and Y.L. contributed equally to this work, taking responsibility for data collection, database maintenance, and writing the original draft of the manuscript. R.L. and H.Z. contributed to the implementation of the machine learning algorithms, as well as database maintenance and follow-up activities. M.Z., Y.L., and C.L. were involved in patient screening and enrollment. D.J. assisted in the development of the software. L.R., Z.C., and Y.H. conceived the study, provided guidance, and participated in the validation and review of the manuscript. All authors have read and approved the final version of the manuscript. More than one author has directly accessed and verified the underlying data reported in the manuscript, ensuring the integrity of the research.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>This study utilized data from the Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients with Percutaneous Coronary Intervention and High Bleeding Risk (PPP-PCI) registry database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05369442">NCT05369442</ext-link>).</p></sec><sec><title>Guarantor</title><p>All the authors accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The datasets used during of the current study are available from the corresponding authors upon reasonable request.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawton</surname><given-names>JS</given-names></name><name name-style="western"><surname>Tamis-Holland</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bangalore</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</article-title>. <source>Circ</source><year>2022</year>;<volume>145</volume>:e4-e17. Erratum in: Circulation <comment>2022;145:e771</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000001039</pub-id><pub-id pub-id-type="pmid">34882436</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>D</given-names></name><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><name name-style="western"><surname>Dangas</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients</article-title>. <source>J Am Coll Cardiol</source><year>2020</year>;<volume>75</volume>:<fpage>2711</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">32466887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.03.070</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueki</surname><given-names>Y</given-names></name><name name-style="western"><surname>B&#228;r</surname><given-names>S</given-names></name><name name-style="western"><surname>Losdat</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Validation of the academic research consortium for high bleeding risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores</article-title>. <source>EuroIntervention</source><year>2020</year>;<volume>16</volume>:<fpage>371</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">32065586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4244/EIJ-D-20-00052</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Natsuaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Shiomi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention</article-title>. <source>Circ Cardiovasc Interv</source><year>2019</year>;<volume>12</volume>:<fpage>e008307</fpage>.<pub-id pub-id-type="pmid">31707804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.119.008307</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Kadota</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry</article-title>. <source>EuroIntervention</source><year>2021</year>;<volume>16</volume>:<fpage>1154</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">32624464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4244/EIJ-D-20-00345</pub-id><pub-id pub-id-type="pmcid">PMC9725071</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subherwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Bach</surname><given-names>RG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>AY</given-names></name><etal/></person-group>. <article-title>Baseline risk of major bleeding in non&#8211;ST-segment&#8211;elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score</article-title>. <source>Circ</source><year>2009</year>;<volume>119</volume>:<fpage>1873</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.108.828541</pub-id><pub-id pub-id-type="pmcid">PMC3767035</pub-id><pub-id pub-id-type="pmid">19332461</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrow</surname><given-names>DA</given-names></name><name name-style="western"><surname>Antman</surname><given-names>EM</given-names></name><name name-style="western"><surname>Charlesworth</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy</article-title>. <source>Circ</source><year>2000</year>;<volume>102</volume>:<fpage>2031</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.102.17.2031</pub-id><pub-id pub-id-type="pmid">11044416</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ducrocq</surname><given-names>G</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>JS</given-names></name><name name-style="western"><surname>Baron</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>On behalf of the REACH Investigators, risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis</article-title>. <source>Eur Heart J</source><year>2010</year>;<volume>31</volume>:<fpage>1257</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">20181681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehq021</pub-id><pub-id pub-id-type="pmcid">PMC2869443</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baber</surname><given-names>U</given-names></name><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><name name-style="western"><surname>Giustino</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>67</volume>:<fpage>2224</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">27079334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2016.02.064</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quer</surname><given-names>G</given-names></name><name name-style="western"><surname>Arnaout</surname><given-names>R</given-names></name><name name-style="western"><surname>Henne</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnaout</surname><given-names>R</given-names></name></person-group>. <article-title>Machine learning and the future of cardiovascular care: JACC state-of-the-art review</article-title>. <source>J Am Coll Cardiol</source><year>2021</year>;<volume>77</volume>:<fpage>300</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">33478654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.030</pub-id><pub-id pub-id-type="pmcid">PMC7839163</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libbrecht</surname><given-names>MW</given-names></name><name name-style="western"><surname>Noble</surname><given-names>WS</given-names></name></person-group>. <article-title>Machine learning applications in genetics and genomics</article-title>. <source>Nat Rev Genet</source><year>2015</year>;<volume>16</volume>:<fpage>321</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">25948244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg3920</pub-id><pub-id pub-id-type="pmcid">PMC5204302</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Fatemifar</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility</article-title>. <source>BMC Med</source><year>2021</year>;<volume>19</volume>:<fpage>85</fpage>.<pub-id pub-id-type="pmid">33820530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-021-01940-7</pub-id><pub-id pub-id-type="pmcid">PMC8022365</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Laranjo</surname><given-names>L</given-names></name><name name-style="western"><surname>Klimis</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Machine-learning versus traditional approaches for atherosclerotic cardiovascular risk prognostication in primary prevention cohorts: a systematic review and meta-analysis</article-title>. <source>Eur Heart J Qual Care Clin Outcomes</source><year>2023</year>;<volume>9</volume>:<fpage>310</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">36869800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ehjqcco/qcad017</pub-id><pub-id pub-id-type="pmcid">PMC10284268</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Revised Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) Guideline: an update for the age of Artificial Intelligence</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100081</fpage>.</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Prognostic analysis and an appropriate antiplatelet strategy for patients with percutaneous coronary intervention and high bleeding risk: rationale and protocol for a multi-center cohort study, cardiology discovery</article-title>. <source>Cardiol Dis</source> n.d.;<volume>4</volume>:<fpage>213</fpage>&#8211;<lpage>20</lpage>.</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>P</given-names></name><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><name name-style="western"><surname>Colleran</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research Consortium for high bleeding risk</article-title>. <source>Eur Heart J</source><year>2019</year>;<volume>40</volume>:<fpage>2632</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">31116395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehz372</pub-id><pub-id pub-id-type="pmcid">PMC6736433</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutlip</surname><given-names>DE</given-names></name><name name-style="western"><surname>Windecker</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Clinical end points in coronary stent trials: a case for standardized definitions</article-title>. <source>Circ</source><year>2007</year>;<volume>115</volume>:<fpage>2344</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.106.685313</pub-id><pub-id pub-id-type="pmid">17470709</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Lundberg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-I</given-names></name></person-group>. <article-title>A unified approach to interpreting model predictions</article-title>, in: <conf-name>Proceedings of the 31st International Conference on Neural Information Processing Systems</conf-name>, <publisher-name>Curran Associates Inc</publisher-name>., <conf-loc>Red Hook, NY, USA</conf-loc>, <year>2017</year>: pp. <fpage>4768</fpage>&#8211;<lpage>77</lpage>.</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>JC</given-names></name></person-group>. <article-title>Enhanced recursive feature elimination</article-title>, <conf-name>Sixth International Conference on Machine Learning and Applications (ICMLA 2007)</conf-name> (<year>2007</year>) <fpage>429</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1109/ICMLA.2007.35</pub-id>.</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>Tailoring antithrombotic regimens for percutaneous coronary intervention patients with high bleeding and ischemic risk (TAILOR-BIRISK): individualized management and genotype-guided de-escalation</article-title>. <source>Rcm</source><year>2023</year>;<volume>24</volume>:<fpage>348</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.31083/j.rcm2412348</pub-id><pub-id pub-id-type="pmcid">PMC11272840</pub-id><pub-id pub-id-type="pmid">39077083</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>The management and antithrombotic strategies of patients with coronary artery disease and high bleeding risk</article-title>. <source>Curr Cardiol Rep</source><year>2023</year>;<volume>25</volume>:<fpage>669</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">37285104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11886-023-01893-8</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis</article-title>. <source>Coron Artery Dis</source><year>2022</year>;<volume>33</volume>:<fpage>580</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">36178984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCA.0000000000001180</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R-C</given-names></name><name name-style="western"><surname>Dewi</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S-W</given-names></name><name name-style="western"><surname>Caraka</surname><given-names>RE</given-names></name></person-group>. <article-title>Selecting critical features for data classification based on machine learning methods</article-title>. <source>J Big Data</source><year>2020</year>;<volume>7</volume>:<fpage>52</fpage>.</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scavuzzo</surname><given-names>CM</given-names></name><name name-style="western"><surname>Scavuzzo</surname><given-names>JM</given-names></name><name name-style="western"><surname>Campero</surname><given-names>MN</given-names></name><etal/></person-group>. <article-title>Feature importance: opening a soil-transmitted helminth machine learning model via SHAP</article-title>. <source>Infect Dis Model</source><year>2022</year>;<volume>7</volume>:<fpage>262</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">35224316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.idm.2022.01.004</pub-id><pub-id pub-id-type="pmcid">PMC8844643</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KT</given-names></name><name name-style="western"><surname>Park</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Heo</surname><given-names>T-Y</given-names></name></person-group>. <article-title>Interpretation of ensemble learning to predict water quality using explainable artificial intelligence</article-title>. <source>Sci Total Environ</source><year>2022</year>;<volume>832</volume>:<fpage>155070</fpage>.<pub-id pub-id-type="pmid">35398119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2022.155070</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Numasawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>I</given-names></name><name name-style="western"><surname>Sawano</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Relation of baseline hemoglobin level to in-hospital outcomes in patients who undergo percutaneous coronary intervention (from a Japanese multicenter registry)</article-title>. <source>Am J Cardiol</source><year>2018</year>;<volume>121</volume>:<fpage>695</fpage>&#8211;<lpage>702</lpage>.<pub-id pub-id-type="pmid">29361289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2017.12.007</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagao</surname><given-names>K</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Credo-Kyoto PCI CABG registry cohort-2, RESET, and NEXT investigators, prognostic impact of baseline hemoglobin levels on long-term thrombotic and bleeding events after percutaneous coronary interventions</article-title>. <source>J Am Heart Assoc</source><year>2019</year>;<volume>8</volume>:<fpage>e013703</fpage>.<pub-id pub-id-type="pmid">31701786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.119.013703</pub-id><pub-id pub-id-type="pmcid">PMC6915278</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahit</surname><given-names>MC</given-names></name><name name-style="western"><surname>Korjian</surname><given-names>S</given-names></name><name name-style="western"><surname>Daaboul</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Abstract 13238: persistence of high rates of major adverse cardiovascular events at 1 year post-myocardial infarction in patients with multivessel disease</article-title>. <source>A Syst Lit Rev Circ</source><year>2023</year>;<volume>148</volume>:<fpage>A13238</fpage>&#8211;<lpage>A13238</lpage>.</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kizer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bella</surname><given-names>JN</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS)</article-title>. <source>Am Heart J</source><year>2006</year>;<volume>151</volume>:<fpage>412</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">16442908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2005.04.031</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>&#946;-hydroxybutyrate exacerbates hypoxic injury by inhibiting HIF-1&#945;-dependent glycolysis in cardiomyocytes-adding fuel to the fire?</article-title><source>Cardiovasc Drugs Ther</source><year>2022</year>;<volume>36</volume>:<fpage>383</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">34652582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10557-021-07267-y</pub-id><pub-id pub-id-type="pmcid">PMC9090701</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Circulating &#946;-hydroxybutyrate levels are associated with major adverse clinical events in patients with acute myocardial infarction</article-title>. <source>Nutr Metab Cardiovasc Dis</source><year>2025</year>;<volume>35</volume>:<fpage>103762</fpage>.<pub-id pub-id-type="pmid">39561688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2024.10.002</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name></person-group>. <article-title>The correlation between albumin-corrected anion gap and prognosis in patients with acute myocardial infarction</article-title>. <source>ESC Heart Failure</source><year>2024</year>;<volume>11</volume>:<fpage>826</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">38164072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ehf2.14639</pub-id><pub-id pub-id-type="pmcid">PMC10966208</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>A</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>HA</given-names></name><name name-style="western"><surname>Panza</surname><given-names>JA</given-names></name></person-group>. <article-title>The initial anion gap is a predictor of mortality in acute myocardial infarction</article-title>. <source>Coron Artery Dis</source><year>2006</year>;<volume>17</volume>:<fpage>409</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">16845247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00019501-200608000-00002</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Serum anion gap is associated with risk of all-cause mortality in critically ill patients with acute myocardial infarction</article-title>. <source>Int J Gen Med</source><year>2022</year>;<volume>15</volume>:<fpage>223</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">35023960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJGM.S336701</pub-id><pub-id pub-id-type="pmcid">PMC8747706</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>